BioCryst Pharmaceuticals, Inc. - Common Stock — 현금 흐름 (NASDAQ:BCRX)

Financials

영업활동으로 인한 현금 -137.22 M-142.16 M-161.85 M-95.14 M-52.02 M347.37 M 313.1 M 투자 활동으로 인한 현금 -6.86 M15.8 M-128.24 M-131.5 M52.59 M-13.69 M -309.44 M 재무활동으로 인한 현금 302.7 M359.67 M88.03 M32.48 M-5.76 M-349.93 M 62.09 M 잉여 현금 흐름 -137.73 M-144.54 M-163.2 M-97.31 M-53.14 M344.9 M 310.37 M

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

BCRX

Financials

BioCryst Pharmaceuticals, Inc. - Common Stock

뉴스

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - BioCryst Pharma (NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

ValuEngine Weekly Market Summary And Commentary

Micron and Intel among market cap stock movers on Monday

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript

TD Cowen, 바이오크리스트 ’매수’ 등급 재확인

TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth

BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates

BioCryst full year 2025 slides: record profit, injectable expansion

바이오크리스트 Q4 실적, 수익 예상치를 넘어

BioCryst earnings beat by $1.08, revenue topped estimates